1098 0 Kommentare Survey of Pharma and Large-cap Biotech Shows Significant Investment in Regenerative Medicine - Seite 2

The most common organizational structure for the companies' regenerative medicine efforts was through vertically integrated R&D units;

The therapeutic areas considered to have the most opportunity were cardiovascular disease, oncology, neurodegenerative disease, monogenic disorders and ocular disease, with wound healing and burns having, perhaps, the greatest near-term potential;

The companies surveyed feel regenerative medicine products have the ability to succeed within current regulatory constructs;

Product consistency and lack of standards is possibly the single greatest challenge facing the field;

Many feel the difficult financing market has impacted the ability of small companies to run high quality clinical trials.

"The support of large pharmaceutical and biotech companies is critical to the success of the regenerative medicine field, and having this valuable insight will allow us to better understand how to work with this group of companies," said Robert A. Preti, Ph.D., President, PCT; Chief Scientific Officer, NeoStem, Inc. and co-chair of ARM's Science and Technology Committee. "It is encouraging to see that the sector is of high interest to the group, and we are pleased with their commitment to the field."

About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 155 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit www.alliancerm.org.